Investors Met With Slowing Returns on Capital At TMC Life Sciences Berhad (KLSE:TMCLIFE)

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. In light of that, when we looked at TMC Life Sciences Berhad (KLSE:TMCLIFE) and its ROCE trend, we weren't exactly thrilled.

Understanding Return On Capital Employed (ROCE)

For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. Analysts use this formula to calculate it for TMC Life Sciences Berhad:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

0.025 = RM26m ÷ (RM1.1b - RM61m) (Based on the trailing twelve months to June 2022).

So, TMC Life Sciences Berhad has an ROCE of 2.5%. In absolute terms, that's a low return and it also under-performs the Healthcare industry average of 26%.

View our latest analysis for TMC Life Sciences Berhad

While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you'd like to look at how TMC Life Sciences Berhad has performed in the past in other metrics, you can view this free graph of past earnings, revenue and cash flow.

So How Is TMC Life Sciences Berhad's ROCE Trending?

There are better returns on capital out there than what we're seeing at TMC Life Sciences Berhad. Over the past five years, ROCE has remained relatively flat at around 2.5% and the business has deployed 45% more capital into its operations. This poor ROCE doesn't inspire confidence right now, and with the increase in capital employed, it's evident that the business isn't deploying the funds into high return investments.

The Key Takeaway

In conclusion, TMC Life Sciences Berhad has been investing more capital into the business, but returns on that capital haven't increased. And in the last five years, the stock has given away 25% so the market doesn't look too hopeful on these trends strengthening any time soon. Therefore based on the analysis done in this article, we don't think TMC Life Sciences Berhad has the makings of a multi-bagger.

One more thing to note, we've identified 1 warning sign with TMC Life Sciences Berhad and understanding this should be part of your investment process.

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.